Depomed, Inc. To Report Fourth Quarter Fiscal Year 2014 Financial Results On Monday, February 23, 2015

NEWARK, Calif., Feb. 12, 2015 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release fourth quarter fiscal year 2014 financial results after the market closes on Monday, February 23, 2015. The Company will host a conference call beginning at 4:30 pm EST, 1:30 pm PST to discuss its results.

Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available via a live webcast on the investor relations section of Depomed's website at http://www.depomed.com. Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.

About Depomed

Depomed is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders.  Gralise^® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia. CAMBIA^® (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks with or without aura in adults (18 years of age or older). Zipsor^® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain in adults.  Lazanda^® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Gralise and various partner product candidates are formulated with Depomed's proven, proprietary Acuform^® drug delivery technology. Depomed has announced the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. which is expected to close in the second quarter of 2015. The NUCYNTA franchise includes NUCYNTA^® ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment, and NUCYNTA^® (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults. Additional information about Depomed may be found at www.depomed.com.

CONTACT:

August J. Moretti  
Depomed, Inc.
510.744.8000
amoretti@depomed.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/depomed-to-report-fourth-quarter-fiscal-year-2014-financial-results-on-monday-february-23-2015-300034725.html

SOURCE Depomed, Inc.